Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA ...

In its yearly survey of international clinicians and patients, Philips illustrated significant gaps in people’s trust when it ...

The medtech association AdvaMed went to Capitol Hill today to make the case that the medical device industry should be exempt ...

Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate ...

Julius Clinical is intertwining its roots with that of Peachtree BioResearch Solutions. | Netherlands-based Julius Clinical ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

When it comes to training artificial intelligence, OpenAI and Babylon Biosciences have shown that experienced hands can help ...

Siemens Healthineers announced plans to relocate some of the manufacturing for its Varian radiotherapy division from Mexico ...

Industry layoffs continue to accelerate, this time hitting RA Capital’s biotech incubator, according to Stat News ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Kyverna Therapeutics may consider it had an “exceptional start to the year,” but that didn’t immunize the cell therapy ...